The prevalence of obesity has been increasing during the last 30 years and globally, more than 760 million people have obesity. Obesity is associated with an increased risk of developing comorbidities, including type 2 diabetes (T2D), dyslipidemia, hypertension, cardiovascular disease (CVD), obstructive sleep apnea, Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NAFLD/NASH), urinary incontinence, several types of cancers, and increased mortality. In addition, individuals with obesity experience reduced health-related quality of life including reduced physical function. Several associations, organizations and individual countries have recognized that obesity should be treated as a chronic disease.
This study is being conducted to look at how well the new investigational medicine CagriSema compared to the medicine called Tirzepatide (recently approved by the FDA) helps people with obesity to lose weight. CagriSema is a combination of Cagrilintide and Semaglutide. Both can lower body weight, and they appear to do so more when combined than alone. Doctors can prescribe Semaglutide to treat people with obesity. Cagrilintide is a new investigational medicine under development.
Qualified participants will:
Receive compensation for time and travel